非小细胞肺癌Fas/FasL基因的定量表达及临床意义
|
摘要
目的探讨Fas和FasL mRNA在非小细胞肺癌(NSCLC)组织中的表达及临床意义。方法采用实时荧光定量RT-PCR法检测Fas和FasL mRNA在NSCLC及正常肺组织中的表达。结果在NSCLC组织中，鳞癌与腺癌肺组织中Fas mRNA(t=1.9773，P=0.0540)及FasL mRNA(t=1.5797，P=0.1210)的表达量无明显差别(P＞0.05)；在NSCLC组织中，Fas mRNA表达显著低于正常肺组织(t′=-5.6634，P＜0.05)，并与NSCLC的病理分级(F=3.81，P=0.0296)、临床分期(F=5.43，P=0.0029)及淋巴结转移(t=2.6621，P=0.0107)有关(P＜0.05)；FasL mRNA表达显著高于正常肺组织(t′=4.8258，P＜0.05)，并与NSCLC的病理分级(F=33.31，P=0.0000)、临床分期(F=9.82，P=0.0000)及淋巴结转移(t′=3.6015，t′(0.0500)=2.0627)有关(P＜0.05)。分期越早，分化越高，无淋巴结转移时，Fas mRNA表达越高，FasL mRNA表达量越低；分期越晚，分化越低，有淋巴结转移时，Fas mRNA表达越低，FasL mRNA表达越高。Fas和FasL mRNA表达之间无相关性(rs=0.2129，P＞0.05)。结论Fas和FasL mRNA表达与肺癌发生、发展、侵袭、转移及恶性程度密切相关，对判断肺癌恶性程度及治疗预后有重要参考价值。
Objective To study the quantitative expression and clinicalsignificance of Fas and FasL mRNA in non-small cell lung cancer(NSCLC).Methods Real-time fluorescent quantitative RT-PCR method Was applied toinvestigate the quantitative expression of Fas and FasL mRNA in NSCLC andnormal lung tissue. Results In NSCLC, The levels of Fas mRNA(t=1.9773, P=0.0540) and FasL mRNA (t=1.5797, P=0.1210) were of no differencebetween squamous carcinoma and adencarcinoma (P＞0.05).The levels of Fas mRNAexpression in NSCLC were significantly lower than those in normal tissues(t'=-5.6634, P＜0.05), and positive expression of Fas mRNA was correlatedwith pathological grades(F=3.81, P=0.0296)、clinical stages(F=5.43,P=0.0029)and lymphatic metastasis(t=2.6621, P=0.0107), (P＜0.05);The levelsof FasL mRNA expression in NSCLC were singnificantly higher than those innormal tissues (t'=4.8258, P＜0.05), and positive expression of FasL mRNAwas correlated with pathological grades(F=33.31, P=0.0000)、clinicalstages(F=9.82, P=0.0000)and lymphatic metastasis(t'=3.6015, t'(0.0500)=2.0627), (P＜0.05); The positive expression levels of Fas mRNA inNSCLC showed negative correlation with that of differentiation and positivecorrelation with that of lymph node metastasis and clinical stages; And thepositive expression levels of FasL mRNA in NSCLC showed positive correlationwith that of differentiation and positive correlation with that of lymph nodemetastasis and clinical stages. There was no correlation in the expressionsbetween Fas and FasL mRNA (rs=0.2129, P＞0.05). Conclusions Abnormalexpression of Fas and FasL mRNA act correlatively to the originality,development、infiltration、metastasis and malignancy, The expression ofFas and FasL mRNA presents singnificance in evaluation of the malignancy andits theraputic prognosis of NSCLC.
Objective To study the quantitative expression and clinicalsignificance of Fas and FasL mRNA in non-small cell lung cancer(NSCLC).Methods Real-time fluorescent quantitative RT-PCR method Was applied toinvestigate the quantitative expression of Fas and FasL mRNA in NSCLC andnormal lung tissue. Results In NSCLC, The levels of Fas mRNA(t=1.9773, P=0.0540) and FasL mRNA (t=1.5797, P=0.1210) were of no differencebetween squamous carcinoma and adencarcinoma (P＞0.05).The levels of Fas mRNAexpression in NSCLC were significantly lower than those in normal tissues(t'=-5.6634, P＜0.05), and positive expression of Fas mRNA was correlatedwith pathological grades(F=3.81, P=0.0296)、clinical stages(F=5.43,P=0.0029)and lymphatic metastasis(t=2.6621, P=0.0107), (P＜0.05);The levelsof FasL mRNA expression in NSCLC were singnificantly higher than those innormal tissues (t'=4.8258, P＜0.05), and positive expression of FasL mRNAwas correlated with pathological grades(F=33.31, P=0.0000)、clinicalstages(F=9.82, P=0.0000)and lymphatic metastasis(t'=3.6015, t'(0.0500)=2.0627), (P＜0.05); The positive expression levels of Fas mRNA inNSCLC showed negative correlation with that of differentiation and positivecorrelation with that of lymph node metastasis and clinical stages; And thepositive expression levels of FasL mRNA in NSCLC showed positive correlationwith that of differentiation and positive correlation with that of lymph nodemetastasis and clinical stages. There was no correlation in the expressionsbetween Fas and FasL mRNA (rs=0.2129, P＞0.05). Conclusions Abnormalexpression of Fas and FasL mRNA act correlatively to the originality,development、infiltration、metastasis and malignancy, The expression ofFas and FasL mRNA presents singnificance in evaluation of the malignancy andits theraputic prognosis of NSCLC.
引文
1 阳成波，印遇龙，黄瑞林，等．实时定量RT-PCR的原理及方法．免疫学杂志，2003，S1：145-150．
2 GiuliettiA, Overbergh L, Valckx D, et al. An overview of real-time quantitative PCR:applications to quantify cytokine gene expression[J]. Methods, 2001, 25(4): 386-401.
3 罗勇军，刘昕．实时荧光定量PCR标准品的制备及应用．重庆医学，2005，34(3)：414-415．
4 胡颖，许凯黎．细胞凋亡机制研究的新进展．《肿瘤》，2001，9，21(5)：389-391．
5 王滨；齐荣义(综述)；郑维国(审校)．Fas／FasL系统与肿瘤的免疫赦免．医学综述，2004．05．15：10(5)：257-258．
6 Maher S, Toomey D, Condron C, et al. Activation induced cell death: thecontroversial role of Fas and Fas ligand in immune privilege and tumour conterattack[J]. Immunol Cell Biol, 2002; 80(2): 131-137.
7 Ferguson TA, Griffith TS. The role of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune response. Chem Immunol Allergy. 2007; 92: 140-154. Review
8 O'Brien DI, Nally K,Kelly RG, et al. Targeting the Fas/Fas ligand pathway in cancer. Expert Opin rher Targets. 2005 Oct;9(5):1031-1044. Review.
9 刘传杰；张杰．FasL基因表达调控研究进展．中国生物工程杂志，2004，24(4)：7-11．
10 张明刚；曹雪涛(审校)．Fas／FasL系统、杀伤性DC与免疫耐受．国外医学·免疫学分册，2004，27(5)：267-270．
11 Maher S, Toomey D, Condron C, et al. Activation-induced cell death:the controversial role of Fas and Fas ligand in immune privilege and tumour conterattack[J]. Immunol Cell Bioi, 2002; 80(2): 131-137.
12 Nambu Y, Hughes SJ, Rehemtull A, et al. Lack of cell surface Fas/Apo-1 expression in pulmonary adenocarcinomous[J]. Clin In-vest, 1998, 101(10): 1102-1110.
13 Myong NH. Tissue microarray analysis of Fas and FasL expressions in human non-small cell lung carcinomas; with reference to the p53 and bcl-2 overexpressions[J]. Korean Med Sci. 2005 0ct; 20(5): 770-776.
14 Viard Leveugle I, Veyrenc S,French LE, et al. Frequent loss of Fas expression and function in human lung tumours with over expression of FasL in small cell lung carcinoma[J]. Pat hol, 2003, 201(2): 268-277.
15 Esposito V, Baldi A, Liuzzi G, et al. Analysis of Fas (Apo-1/CD95) expression in non-small cell lung cancer[J]. Anticancer Res. 2003 Nov-Dec;23(6C):4901-4905.
16 Omoteyama K, Inoue S. The variation in Fas localization and the changes in Fas expression level upon stimulation with growth factors[J]. Biochem Biophys Res Commun. 2007, 2, 353(1): 159-163.
17 向青，徐波，徐梅．Fas／FasL途径介导的人肺癌细胞免疫逃逸．中国病理生理杂志，2006，22(1)：168-171．
18 Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer. 2004 Jun 1; 100(11): 2281-2291. Review.
19 Zhang X, Niao X, Sun T, et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer[J]. Ned Genet. 2005 Jun; 42(6): 479-484.
20 Gordon N, Arndt CA, Hawkins DS, et al. Fas expression in lung metastasis from osteosarcoma patients[J]. Pediatr Hematol Oncol. 2005 Nov; 27(11): 611-615.
21 Shin NS, Kim HS, Lee SH, et al. Alterations of Fas-pathway genes Associated with nodal metastasis in non-small cell lung cancer[J]. Oncogene, 2002, 21(26): 4129-4136.
22 Wiener Z, Ontsouka EC, Jakob S, et al. Synergistic induction of the Fas(CD95) ligand promoter by Max and NFkappaB in human non-small lung cancer cells[J]. Exp Cell Res. 2004 Sep 10; 299(1): 227-235.
23 邹悦，魏煜程，沈毅．非小细胞肺癌患者手术前后血清可溶性Fas和FasL浓度的变化及其临床意义[J]．中华肿瘤防治杂志，2006，13(11)：841-843．
24 徐音像，蒋耀光，林一丹，等．Fas、FasL蛋白在非小细胞肺癌组织的表达及其生物学意义．山东医药，2006，(31)：15-16．
25 Scholz N, Cinatl J. Fas/FasL interaction: a novel immune therapy approach with immobilized bioldgicals. Ned Res Rev. 2005 Nay; 25(3): 331-342. Review.
26 Mollinedo F, Gajate C. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist Updat. 2006 Feb-Apr;9(1-2):51-73. Epub 2006 May 9. Review.
27 Odoux C, Albers A, Amoscato AA, et al. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small cell lung cancer[J]. Cancer, 2002,97(4):458-465.
28 Raez L E, Cassileth PA, Schlesselman JJ, et al. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer[J]. Clin Oncol, 2004, 22(14): 2800-2807.
29 张蓓．实时荧光定量PCR的研究进展及其应用．国外医学．临床生物化学与检验学分册，2003，06：327-329．
1 肖斌，朱永红，邹全明，等．树突状细胞在调节性T细胞产生中的作用．中国免疫学杂志，2007，(01)：85-88．
2 Mielf CJM. T-cell immunity against tumors, a delicate balancing act involving dendritic cell[J].Pathol Biol, 2001,49: 498-499.
3 Harada N, Kodama N, Nanba H, et al. Relationship between dendritic cell and D-fraction-induced Th-1 dominant response in BALB/c tumor-bearing mice[J]. Cancer Letters, 2003,192(2): 181-187.
4 Auffermann-Gretzingers, Emmet B. K, Shoshana Levy. et al. Impaired dendritic cellmaturation in patientswith chronic, but not resolved, hepatitis C virus infection[J]. Blood, 2001,97: 3171-3176.
5 Kurabayashi A, Furihata M, Matsumoto M, et al. Distribution of tumor-infiltrating dendritic cells in human non-small cell lung carcinoma in relation to apoptosis[J].Pathol Int. 2004 May; 54(5): 302-310.
6 Troy A, Davidson P, Atkinson C, et al. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer[J]. Urol. 1998 Jul; 160(1): 214-219.
7 Berthier VO. Gaucherand M, Peguet NJ, et al. Human melanoma cellsinhibit the earliest differentiation steps of human Langerhans cell precurors but failed to affect the functional maturation of epidermal Langerhans cells[J]. Br J Cancer, 2001, 85(12): 1944-1951.
8 Lotze MT, Thomson AW, editors. Dendriticcells: biology and clinical applications[M]. San Diego CA: Academic Press, 1999.673-692.
9 Esche C, Lokshin A, Shurin GV, et al. Tumor's other immune targets: dendrtic cells[J]. Leukoe Biol, 1999,66: 336-344.
10 Makarenkova VP, Shurin GV, Tourkova IL, et al. Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells[J]. Neuroimmunol, 2003,145(1-2): 55-67.
11 tzmer R, Li W, Sutterwala S, et al.A tumor-associated glycoprotein that blocks MHC class Ⅱ dependent antigen presentation by dendritic cells[J]. Immunol, 2004,173(2): 1023-1032.
12 Fogel-PetrovicM, Long JA, Knight DA, et al. Activated human dendritic cells express inducible cyclo-oxygenase and synthesizep rostaglandin E2 but not prostaglandin D2[J].Immunol Cell Biol. 2004,82(1): 47-54.
13 Ratta M, Fagnoni F, Curti A, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6[J]. Blood, 2002,100(1): 230-237.
14 Makarenkova VP, Shurin GV, Tourkova IL, et al. Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells[J]. Neuroimmunol, 2002,145(1-2): 55-67.
15 Katsenelson NS, Shurin GV, Bykovskaia SN, et al. Human small cell lung carcinoma and carcinoid tumor regulate dendritic cell maturation and function[J]. Mod Pathol. 2001 Jan;14(1): 40-45.
16 Kanto T, Kalinski P, Hunter OC, et al. Ceramide mediates tumor induced dendritic cell apoptosis[J]. Immunol, 2001, 167(7): 3773-3784.
17 Wolfl M, Batten WY, Posovszky C, et al. Gangliosides inhibit the development from monocytes to dendritic cells[J]. Clin Exp Immunol, 2002,130(3): 441-448.
18 Peguet-Navarro J, Sportouch M, Popa I, et al. Gangliosdes from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis[J].Immunol, 2003,170(7): 3488-3494.
19 Balkir L, rourkova IL, Makarenkova vp, et al. Comparative analysis of dendritic cells transduced with different anti-apoptotic molecules: sensitivitv to tumor-induced apoptosis[J]. Gene Med. 2002.6(5): 537-544.
20 Salvadori S, Martinelli G, Zier K, et al. Resection of solid tumors reverses T cell defects and restores protective immunity[J]. Immunol, 2000,164(4): 2214-2220.
21 施敏敏，刘炳亚，李强等．CD4+CD25+T细胞在CD8+T细胞抗肿瘤免疫中的调节作用．现代免疫学，2005，25(5)：384-388．
22 Adler AJ, Marsh DW, Yochum GS, et aI. CD4~+ T cell tolerance to parechymale self-antigens requirs presentation by bone marrow-derived antigen-presenting cells[J]. Exp Med, 1998,187(10): 1555-1564.
23 Matsui S, Ahlers JD, Vortmeyer AO, et al. A model for CD8~+CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL[J].Immunol, 1999,165(1): 184-193
24 Chai JG, Vendetti S, Amofah E, et al. CD152 ligtation by CD80 on T cells is required for the induction of unresponsiveness by costimulation-deficient antigen presentation[J]. Immunol, 2000, 165 (6): 3037-3042.
25 王亮丽，张登海．Fas系统与肿瘤免疫逃逸．国外医学输血及血液分册，2000，23(6)：308-310．
26 任含平(综述)；施广霞(审校)．Fas信号转导与其抑制机制．国外医学·生理、病理科学与临床分册．2004，24(4)：328-331．
27 陆茜，李宁丽．Fas介导细胞凋亡及相关免疫调节作用．细胞生物学杂志，2006，(04)：543-546．
28 Viard Leveugle I, Veyrenc S, French L E, et al. Frequent loss of Fas expression and function in human lung tumours with over expression of FasL in small cell lung carcinoma[J]. Pat hol, 2003,201(2): 268-277.
29 郑佳，刘复强．Fas／FasL及其临床意义．首都医科大学学报，2004．25(3)：411-414．
30 Maher S, Toomey D, Condron C, et al. Activation induced cell death: the controversial role of Fas and Fas lisand in immune privilese and tumour conterattack[J]. Immunol Cell Biol, 2002;80(2): 131-137.
31 张国强(综述)：蒋耀光；王如文(审校)．Fas／FasL与肿瘤免疫逃避．重庆医学，2004，33(5)：786-788．
32 江中勇，杨凌，陈清勇．Fas／FasL与肺癌关系的研究进展．国外医学·呼吸系统分册，2005，25(2)：115-117．
33 Ivanov VN, Bhoumik A, Krasilnikov M, et al. Cooperation between STAT3 and c-jun suppresses Fas transcription[J]. Mol Cell, 2001,7(3): 517-528.
34 Lee SH, Shin MS, Park WS, et al, Alterations of Fas(Apo-1/CD95) gene in nonsmall cell lung cancer[J].Oncosene, 1999,18(25): 3754-3760.
35 Boldrini L, Faviana P, Gisfredi S, et al. Identification of Fas (APO-1/CD95) and p53 gene mutations in non-small cell lung cancer [J]. Int J 0ncol. 2002; 20(1):155-159.
36 Shin MS, Kim HS, Lee SH, et al. Alterations of Fas pathway series associated with nodal metastasis in non small cell lung cancer [J]. Oncosene, 2002,21(26): 4129-4136.
37 Liu K, Abrams SI.Alterations in Fas expression are characteristic of, but not solely responsible for enhanced metastatic competence[J], Immunol, 2003,170(12): 5973-5978.
38 林一丹(综述)，蒋耀光(审校)．Fas／FasL系统在肿瘤发展过程中的生物学作用．重庆医学，2004，33(2)：201-203．
39 Gloria A, Niehans, Thomas Brunner, Sandra P. Frizelle, et al. Kratzke: human lung carcinomas express Fas ligand[J]. Cancer Research, 1997,57: 1007-1012.
40 Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand -induced apoptosis as a mechanism of immune privilege[J].Science, 1995,270: 1189-1192.
41 Pluygers E, Sadowska A, Chyczewski L, et al. The impact of immune response on lung cancer and the development of new treatment modalities[J]. Lung Cancer, 2001,34(Supp12): S71-S77.
42 Bernstorff WV, Spamjaard RA, Chan A K, et al. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas(Apo-1/CD95)recepors and sberrant expression of functional Fas ligand[J].Surgery, 1999,125(1): 73-84.
43 Cho D, Song H, Kim YM, et al. Endogenous interleukin18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res, 2000,60(10): 2703-2709.
44 Yasuda M, Tanaka Y, Fjii K, et al. CD44 stimulation down regulates Fas expression and Fas mediated apotosis of lung cancer cells[J].Int Immunol, 2001,13(10): 1309-1319.
45 成志强，王晓玫．CD44基因与肺癌研究进展．医学综述，2003，9(6)：335-337．
46 Shimbori M, Kijima H, Sato S, et al. Expression of CD44 in primary lung carcinomas using histological and cytological analyses [J]. Anticancer Res. 2003,23(1A):115-21.
47 Fasano M. Sabatini MT. Wieczorek R. et al. CD44 and its v6 spliced variant in lung tumors: a role in histogenesis[J]. Cancer, 1997,80(1): 34-41.
48 Takigawa N, Segawa Y, Mandai K, et al. Serum CD44 levels in patients with non-small cell lung cancer and their relationship with clinicopathological features[J]. Lung Cancer, 1997,18(2): 147-157.
49 Penno MB, Askin FB, Ma H, et al. High CD44 expression on human mesotheliomas mediates association with hyaluronan[J]. Cancer J Sci Am, 1995,1(3):196-203.
50 Wimmel A, Kogan E, Ramaswamy A, et al. Variant expression of CD44 in preneoplastic lesions of the lung [J]. Cancer, 2001,92(5): 1231-1236.
51 Yasuda M, Tanaka Y, Fujii K, et al. CD44 stimulation down regulates expression and Fas mediated apoptosis of lung cancer cells[J].Int Immunol, 2001,13(10): 1309-1319.
52 刘峰(综述)，楼国良(审校)．Fas／FasL与免疫耐受．国外医学，输血及血液学分 册，2004，27(1)：55-57．
52 江中勇，杨凌，陈清勇．CD(44)与肺癌关系的研究进展．国际呼吸杂志，2006，(02)：115-117．
54 Takahashi K, Takahashi F, Hirama M, et al. Restoration of CD44s in non-small cell lung cancer cells enhanced the irsusceptibility to the macrophagecy to toxicity[J].Lung cancer, 2003,41(2): 145-153.
55 Rawson P, Hermans IF, Huck SP, et al. Immunotherapy with dendritic cells and tumor major histocompatibility complex class derived peptid requirs a high density of antigen on tumor cells[J].Cancer Res, 2000;60(16):4493-4498.
56 Allan PSJ, Colonna M, hanier LL, et al. Tetrameric complexes of human histocompatibility leukocyte antigen(HLA-G) bind to peripheral blood mye]omonocytic cells[J].Exp Med, 1999,189(7): 1149-1156.
57 谢维．MHC基因多态性和肿瘤的发生．现代免疫学，2004，(06)：441-444．
58 Carosella ED, Rouas Freiss N, Paul P, et aI. HLA-G: a tolerance molecule from the major histocompatibility complex[J]. Immunol Today, 1999,20(2): 60-62.
59 Lefebvre S, Antoine M, Uzan S, et al. Specific activation of the non classicl class I histocompatibility HLA-G antigen and expression of the IL-T2 inhibitory receptor in human breast cancer[J].Pathol, 2002,196(3) 252-253.
60 Windl H, Mitsdoerffer M, Hofmeister V, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape[J]. Immunol, 2002,168(9): 4772-4780.
61 Shin JS, Ebersold M, Pypaert M, et al. Surface expression of MHC class Ⅱ in dendritic cells is controlled by regulated ubiquitination[J]. Nature. 2006 Nov 2; 444(7115):115-118.
62 Martin BK, Frelinger JG, Ting J P, et al. Combination gene therapy with CD86 and the MHC class Ⅱ transactivator in the control of lung tumor growth[J]. Immunol, 1999,162(11): 6663-6670.
63 张学光．共刺激分子及其调节网络在特异性免疫应答中的作用及机制．中国免疫学杂志，2004，(01)：26-32．
64 Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-L1 expression[J]. Clin Cancer Res, 2004 aug 1,10(15): 5094-6100.
65 Raez LE, Cassileth PA, Schlesselman JJ, et al. Allogeneic vaccination with a B7-1、HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small cell lung cancer[J]. Clin Oncol, 2004 Jul 15,22(14): 2800-2807.
66 nemr A, Ohta T, Yachie A, et al. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; apotential mechanism forimmune escape[J].Int J Oncol, 2001,18 (1): 33-39.
67 Makarenkova VP, Shurin GV, Tourkova IL, et al. Lung cancer derived bombesin like peptides down-regulate the generation and function of human dendritic cells [J]. Neuroimmunol, 2003,145(1-2): 55-67.
68 Harada N, Kodama N, et al. Relationship between dendritic cell and D-fraction-induced Th-1 dominant response in BALB/c tumor-bearing mice[J]. Cancer Letters, 2003,192(2): 181-187.
69 Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune and tumor immunotherapy by PD-L1 blocked[J]. Proc Natl Acad Sci USA, 2002,99(19): 12293-12297.
70 IshidaM, Iwai Y, Tanaka Y, et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory recep ter PD-L1, in the cells of lymphohematopoietic tissues[J].Immunol Lett, 2002,84(1): 57-62.
71 Curiel TJ, Wei S, Dong H, et al. Blocked of BT-H1 improves myeloid dendritic cell mediated antitumor immunity[J].NatMed, 2003,9(5): 562-567.
72 张燕，孙亚红，徐从高．B7共刺激分子与肿瘤基因治疗．国外医学．肿瘤学分册，2005，(01)：22-24．
2 GiuliettiA, Overbergh L, Valckx D, et al. An overview of real-time quantitative PCR:applications to quantify cytokine gene expression[J]. Methods, 2001, 25(4): 386-401.
3 罗勇军，刘昕．实时荧光定量PCR标准品的制备及应用．重庆医学，2005，34(3)：414-415．
4 胡颖，许凯黎．细胞凋亡机制研究的新进展．《肿瘤》，2001，9，21(5)：389-391．
5 王滨；齐荣义(综述)；郑维国(审校)．Fas／FasL系统与肿瘤的免疫赦免．医学综述，2004．05．15：10(5)：257-258．
6 Maher S, Toomey D, Condron C, et al. Activation induced cell death: thecontroversial role of Fas and Fas ligand in immune privilege and tumour conterattack[J]. Immunol Cell Biol, 2002; 80(2): 131-137.
7 Ferguson TA, Griffith TS. The role of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune response. Chem Immunol Allergy. 2007; 92: 140-154. Review
8 O'Brien DI, Nally K,Kelly RG, et al. Targeting the Fas/Fas ligand pathway in cancer. Expert Opin rher Targets. 2005 Oct;9(5):1031-1044. Review.
9 刘传杰；张杰．FasL基因表达调控研究进展．中国生物工程杂志，2004，24(4)：7-11．
10 张明刚；曹雪涛(审校)．Fas／FasL系统、杀伤性DC与免疫耐受．国外医学·免疫学分册，2004，27(5)：267-270．
11 Maher S, Toomey D, Condron C, et al. Activation-induced cell death:the controversial role of Fas and Fas ligand in immune privilege and tumour conterattack[J]. Immunol Cell Bioi, 2002; 80(2): 131-137.
12 Nambu Y, Hughes SJ, Rehemtull A, et al. Lack of cell surface Fas/Apo-1 expression in pulmonary adenocarcinomous[J]. Clin In-vest, 1998, 101(10): 1102-1110.
13 Myong NH. Tissue microarray analysis of Fas and FasL expressions in human non-small cell lung carcinomas; with reference to the p53 and bcl-2 overexpressions[J]. Korean Med Sci. 2005 0ct; 20(5): 770-776.
14 Viard Leveugle I, Veyrenc S,French LE, et al. Frequent loss of Fas expression and function in human lung tumours with over expression of FasL in small cell lung carcinoma[J]. Pat hol, 2003, 201(2): 268-277.
15 Esposito V, Baldi A, Liuzzi G, et al. Analysis of Fas (Apo-1/CD95) expression in non-small cell lung cancer[J]. Anticancer Res. 2003 Nov-Dec;23(6C):4901-4905.
16 Omoteyama K, Inoue S. The variation in Fas localization and the changes in Fas expression level upon stimulation with growth factors[J]. Biochem Biophys Res Commun. 2007, 2, 353(1): 159-163.
17 向青，徐波，徐梅．Fas／FasL途径介导的人肺癌细胞免疫逃逸．中国病理生理杂志，2006，22(1)：168-171．
18 Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer. 2004 Jun 1; 100(11): 2281-2291. Review.
19 Zhang X, Niao X, Sun T, et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer[J]. Ned Genet. 2005 Jun; 42(6): 479-484.
20 Gordon N, Arndt CA, Hawkins DS, et al. Fas expression in lung metastasis from osteosarcoma patients[J]. Pediatr Hematol Oncol. 2005 Nov; 27(11): 611-615.
21 Shin NS, Kim HS, Lee SH, et al. Alterations of Fas-pathway genes Associated with nodal metastasis in non-small cell lung cancer[J]. Oncogene, 2002, 21(26): 4129-4136.
22 Wiener Z, Ontsouka EC, Jakob S, et al. Synergistic induction of the Fas(CD95) ligand promoter by Max and NFkappaB in human non-small lung cancer cells[J]. Exp Cell Res. 2004 Sep 10; 299(1): 227-235.
23 邹悦，魏煜程，沈毅．非小细胞肺癌患者手术前后血清可溶性Fas和FasL浓度的变化及其临床意义[J]．中华肿瘤防治杂志，2006，13(11)：841-843．
24 徐音像，蒋耀光，林一丹，等．Fas、FasL蛋白在非小细胞肺癌组织的表达及其生物学意义．山东医药，2006，(31)：15-16．
25 Scholz N, Cinatl J. Fas/FasL interaction: a novel immune therapy approach with immobilized bioldgicals. Ned Res Rev. 2005 Nay; 25(3): 331-342. Review.
26 Mollinedo F, Gajate C. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist Updat. 2006 Feb-Apr;9(1-2):51-73. Epub 2006 May 9. Review.
27 Odoux C, Albers A, Amoscato AA, et al. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small cell lung cancer[J]. Cancer, 2002,97(4):458-465.
28 Raez L E, Cassileth PA, Schlesselman JJ, et al. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer[J]. Clin Oncol, 2004, 22(14): 2800-2807.
29 张蓓．实时荧光定量PCR的研究进展及其应用．国外医学．临床生物化学与检验学分册，2003，06：327-329．
1 肖斌，朱永红，邹全明，等．树突状细胞在调节性T细胞产生中的作用．中国免疫学杂志，2007，(01)：85-88．
2 Mielf CJM. T-cell immunity against tumors, a delicate balancing act involving dendritic cell[J].Pathol Biol, 2001,49: 498-499.
3 Harada N, Kodama N, Nanba H, et al. Relationship between dendritic cell and D-fraction-induced Th-1 dominant response in BALB/c tumor-bearing mice[J]. Cancer Letters, 2003,192(2): 181-187.
4 Auffermann-Gretzingers, Emmet B. K, Shoshana Levy. et al. Impaired dendritic cellmaturation in patientswith chronic, but not resolved, hepatitis C virus infection[J]. Blood, 2001,97: 3171-3176.
5 Kurabayashi A, Furihata M, Matsumoto M, et al. Distribution of tumor-infiltrating dendritic cells in human non-small cell lung carcinoma in relation to apoptosis[J].Pathol Int. 2004 May; 54(5): 302-310.
6 Troy A, Davidson P, Atkinson C, et al. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer[J]. Urol. 1998 Jul; 160(1): 214-219.
7 Berthier VO. Gaucherand M, Peguet NJ, et al. Human melanoma cellsinhibit the earliest differentiation steps of human Langerhans cell precurors but failed to affect the functional maturation of epidermal Langerhans cells[J]. Br J Cancer, 2001, 85(12): 1944-1951.
8 Lotze MT, Thomson AW, editors. Dendriticcells: biology and clinical applications[M]. San Diego CA: Academic Press, 1999.673-692.
9 Esche C, Lokshin A, Shurin GV, et al. Tumor's other immune targets: dendrtic cells[J]. Leukoe Biol, 1999,66: 336-344.
10 Makarenkova VP, Shurin GV, Tourkova IL, et al. Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells[J]. Neuroimmunol, 2003,145(1-2): 55-67.
11 tzmer R, Li W, Sutterwala S, et al.A tumor-associated glycoprotein that blocks MHC class Ⅱ dependent antigen presentation by dendritic cells[J]. Immunol, 2004,173(2): 1023-1032.
12 Fogel-PetrovicM, Long JA, Knight DA, et al. Activated human dendritic cells express inducible cyclo-oxygenase and synthesizep rostaglandin E2 but not prostaglandin D2[J].Immunol Cell Biol. 2004,82(1): 47-54.
13 Ratta M, Fagnoni F, Curti A, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6[J]. Blood, 2002,100(1): 230-237.
14 Makarenkova VP, Shurin GV, Tourkova IL, et al. Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells[J]. Neuroimmunol, 2002,145(1-2): 55-67.
15 Katsenelson NS, Shurin GV, Bykovskaia SN, et al. Human small cell lung carcinoma and carcinoid tumor regulate dendritic cell maturation and function[J]. Mod Pathol. 2001 Jan;14(1): 40-45.
16 Kanto T, Kalinski P, Hunter OC, et al. Ceramide mediates tumor induced dendritic cell apoptosis[J]. Immunol, 2001, 167(7): 3773-3784.
17 Wolfl M, Batten WY, Posovszky C, et al. Gangliosides inhibit the development from monocytes to dendritic cells[J]. Clin Exp Immunol, 2002,130(3): 441-448.
18 Peguet-Navarro J, Sportouch M, Popa I, et al. Gangliosdes from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis[J].Immunol, 2003,170(7): 3488-3494.
19 Balkir L, rourkova IL, Makarenkova vp, et al. Comparative analysis of dendritic cells transduced with different anti-apoptotic molecules: sensitivitv to tumor-induced apoptosis[J]. Gene Med. 2002.6(5): 537-544.
20 Salvadori S, Martinelli G, Zier K, et al. Resection of solid tumors reverses T cell defects and restores protective immunity[J]. Immunol, 2000,164(4): 2214-2220.
21 施敏敏，刘炳亚，李强等．CD4+CD25+T细胞在CD8+T细胞抗肿瘤免疫中的调节作用．现代免疫学，2005，25(5)：384-388．
22 Adler AJ, Marsh DW, Yochum GS, et aI. CD4~+ T cell tolerance to parechymale self-antigens requirs presentation by bone marrow-derived antigen-presenting cells[J]. Exp Med, 1998,187(10): 1555-1564.
23 Matsui S, Ahlers JD, Vortmeyer AO, et al. A model for CD8~+CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL[J].Immunol, 1999,165(1): 184-193
24 Chai JG, Vendetti S, Amofah E, et al. CD152 ligtation by CD80 on T cells is required for the induction of unresponsiveness by costimulation-deficient antigen presentation[J]. Immunol, 2000, 165 (6): 3037-3042.
25 王亮丽，张登海．Fas系统与肿瘤免疫逃逸．国外医学输血及血液分册，2000，23(6)：308-310．
26 任含平(综述)；施广霞(审校)．Fas信号转导与其抑制机制．国外医学·生理、病理科学与临床分册．2004，24(4)：328-331．
27 陆茜，李宁丽．Fas介导细胞凋亡及相关免疫调节作用．细胞生物学杂志，2006，(04)：543-546．
28 Viard Leveugle I, Veyrenc S, French L E, et al. Frequent loss of Fas expression and function in human lung tumours with over expression of FasL in small cell lung carcinoma[J]. Pat hol, 2003,201(2): 268-277.
29 郑佳，刘复强．Fas／FasL及其临床意义．首都医科大学学报，2004．25(3)：411-414．
30 Maher S, Toomey D, Condron C, et al. Activation induced cell death: the controversial role of Fas and Fas lisand in immune privilese and tumour conterattack[J]. Immunol Cell Biol, 2002;80(2): 131-137.
31 张国强(综述)：蒋耀光；王如文(审校)．Fas／FasL与肿瘤免疫逃避．重庆医学，2004，33(5)：786-788．
32 江中勇，杨凌，陈清勇．Fas／FasL与肺癌关系的研究进展．国外医学·呼吸系统分册，2005，25(2)：115-117．
33 Ivanov VN, Bhoumik A, Krasilnikov M, et al. Cooperation between STAT3 and c-jun suppresses Fas transcription[J]. Mol Cell, 2001,7(3): 517-528.
34 Lee SH, Shin MS, Park WS, et al, Alterations of Fas(Apo-1/CD95) gene in nonsmall cell lung cancer[J].Oncosene, 1999,18(25): 3754-3760.
35 Boldrini L, Faviana P, Gisfredi S, et al. Identification of Fas (APO-1/CD95) and p53 gene mutations in non-small cell lung cancer [J]. Int J 0ncol. 2002; 20(1):155-159.
36 Shin MS, Kim HS, Lee SH, et al. Alterations of Fas pathway series associated with nodal metastasis in non small cell lung cancer [J]. Oncosene, 2002,21(26): 4129-4136.
37 Liu K, Abrams SI.Alterations in Fas expression are characteristic of, but not solely responsible for enhanced metastatic competence[J], Immunol, 2003,170(12): 5973-5978.
38 林一丹(综述)，蒋耀光(审校)．Fas／FasL系统在肿瘤发展过程中的生物学作用．重庆医学，2004，33(2)：201-203．
39 Gloria A, Niehans, Thomas Brunner, Sandra P. Frizelle, et al. Kratzke: human lung carcinomas express Fas ligand[J]. Cancer Research, 1997,57: 1007-1012.
40 Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand -induced apoptosis as a mechanism of immune privilege[J].Science, 1995,270: 1189-1192.
41 Pluygers E, Sadowska A, Chyczewski L, et al. The impact of immune response on lung cancer and the development of new treatment modalities[J]. Lung Cancer, 2001,34(Supp12): S71-S77.
42 Bernstorff WV, Spamjaard RA, Chan A K, et al. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas(Apo-1/CD95)recepors and sberrant expression of functional Fas ligand[J].Surgery, 1999,125(1): 73-84.
43 Cho D, Song H, Kim YM, et al. Endogenous interleukin18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res, 2000,60(10): 2703-2709.
44 Yasuda M, Tanaka Y, Fjii K, et al. CD44 stimulation down regulates Fas expression and Fas mediated apotosis of lung cancer cells[J].Int Immunol, 2001,13(10): 1309-1319.
45 成志强，王晓玫．CD44基因与肺癌研究进展．医学综述，2003，9(6)：335-337．
46 Shimbori M, Kijima H, Sato S, et al. Expression of CD44 in primary lung carcinomas using histological and cytological analyses [J]. Anticancer Res. 2003,23(1A):115-21.
47 Fasano M. Sabatini MT. Wieczorek R. et al. CD44 and its v6 spliced variant in lung tumors: a role in histogenesis[J]. Cancer, 1997,80(1): 34-41.
48 Takigawa N, Segawa Y, Mandai K, et al. Serum CD44 levels in patients with non-small cell lung cancer and their relationship with clinicopathological features[J]. Lung Cancer, 1997,18(2): 147-157.
49 Penno MB, Askin FB, Ma H, et al. High CD44 expression on human mesotheliomas mediates association with hyaluronan[J]. Cancer J Sci Am, 1995,1(3):196-203.
50 Wimmel A, Kogan E, Ramaswamy A, et al. Variant expression of CD44 in preneoplastic lesions of the lung [J]. Cancer, 2001,92(5): 1231-1236.
51 Yasuda M, Tanaka Y, Fujii K, et al. CD44 stimulation down regulates expression and Fas mediated apoptosis of lung cancer cells[J].Int Immunol, 2001,13(10): 1309-1319.
52 刘峰(综述)，楼国良(审校)．Fas／FasL与免疫耐受．国外医学，输血及血液学分 册，2004，27(1)：55-57．
52 江中勇，杨凌，陈清勇．CD(44)与肺癌关系的研究进展．国际呼吸杂志，2006，(02)：115-117．
54 Takahashi K, Takahashi F, Hirama M, et al. Restoration of CD44s in non-small cell lung cancer cells enhanced the irsusceptibility to the macrophagecy to toxicity[J].Lung cancer, 2003,41(2): 145-153.
55 Rawson P, Hermans IF, Huck SP, et al. Immunotherapy with dendritic cells and tumor major histocompatibility complex class derived peptid requirs a high density of antigen on tumor cells[J].Cancer Res, 2000;60(16):4493-4498.
56 Allan PSJ, Colonna M, hanier LL, et al. Tetrameric complexes of human histocompatibility leukocyte antigen(HLA-G) bind to peripheral blood mye]omonocytic cells[J].Exp Med, 1999,189(7): 1149-1156.
57 谢维．MHC基因多态性和肿瘤的发生．现代免疫学，2004，(06)：441-444．
58 Carosella ED, Rouas Freiss N, Paul P, et aI. HLA-G: a tolerance molecule from the major histocompatibility complex[J]. Immunol Today, 1999,20(2): 60-62.
59 Lefebvre S, Antoine M, Uzan S, et al. Specific activation of the non classicl class I histocompatibility HLA-G antigen and expression of the IL-T2 inhibitory receptor in human breast cancer[J].Pathol, 2002,196(3) 252-253.
60 Windl H, Mitsdoerffer M, Hofmeister V, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape[J]. Immunol, 2002,168(9): 4772-4780.
61 Shin JS, Ebersold M, Pypaert M, et al. Surface expression of MHC class Ⅱ in dendritic cells is controlled by regulated ubiquitination[J]. Nature. 2006 Nov 2; 444(7115):115-118.
62 Martin BK, Frelinger JG, Ting J P, et al. Combination gene therapy with CD86 and the MHC class Ⅱ transactivator in the control of lung tumor growth[J]. Immunol, 1999,162(11): 6663-6670.
63 张学光．共刺激分子及其调节网络在特异性免疫应答中的作用及机制．中国免疫学杂志，2004，(01)：26-32．
64 Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-L1 expression[J]. Clin Cancer Res, 2004 aug 1,10(15): 5094-6100.
65 Raez LE, Cassileth PA, Schlesselman JJ, et al. Allogeneic vaccination with a B7-1、HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small cell lung cancer[J]. Clin Oncol, 2004 Jul 15,22(14): 2800-2807.
66 nemr A, Ohta T, Yachie A, et al. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; apotential mechanism forimmune escape[J].Int J Oncol, 2001,18 (1): 33-39.
67 Makarenkova VP, Shurin GV, Tourkova IL, et al. Lung cancer derived bombesin like peptides down-regulate the generation and function of human dendritic cells [J]. Neuroimmunol, 2003,145(1-2): 55-67.
68 Harada N, Kodama N, et al. Relationship between dendritic cell and D-fraction-induced Th-1 dominant response in BALB/c tumor-bearing mice[J]. Cancer Letters, 2003,192(2): 181-187.
69 Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune and tumor immunotherapy by PD-L1 blocked[J]. Proc Natl Acad Sci USA, 2002,99(19): 12293-12297.
70 IshidaM, Iwai Y, Tanaka Y, et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory recep ter PD-L1, in the cells of lymphohematopoietic tissues[J].Immunol Lett, 2002,84(1): 57-62.
71 Curiel TJ, Wei S, Dong H, et al. Blocked of BT-H1 improves myeloid dendritic cell mediated antitumor immunity[J].NatMed, 2003,9(5): 562-567.
72 张燕，孙亚红，徐从高．B7共刺激分子与肿瘤基因治疗．国外医学．肿瘤学分册，2005，(01)：22-24．